The global demand for Somatostatin Analogs Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Somatostatin Analogues are drugs used in oncological treatment to inhibit the growth of tumours. These drugs when administered block the release of hormones by endocrine glands. They are generally used in patients exhibiting instability to perform a surgery or with invasive tumours. These drugs are given as injections for a period of 4 weeks. They are also used to treat a condition called acromegaly: over secretion of growth hormone in adults. Somatostatin analogues have revolutionised the treatment of neuroendocrine tumours and paediatric tumours.
The market for somatostatin analogues is mainly driven by the growing number of people affected by carcinoid tumours and hormonal disorders. The advanced health care facilities, better diagnosis and technologically advanced pharmaceutical industry will further boost the growth of this market. The various research activities carried out in the pharmaceutical industries for efficient use of these analogues will augment the market growth. Convalescing patients need to be extra careful by following social distancing during COVID-19 since they have a weak immune system. This market can be hampered by the side effects associated, prices of raw materials and stringent rules put forth by the government in the use of these drugs. Lack of awareness of these treatment methods can hinder this market as well.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of somatostatin analogs.
The entire somatostatin analogs market has been sub-categorized into type and application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Neuroendocrine Tumors (NETs)
This section covers regional segmentation which accentuates on current and future demand for somatostatin analogs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Europe Somatostatin Analogs Market By Revenue (USD MN)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the somatostatin analogs market include Novartis AG, Sun Pharmaceutical Industries Ltd., MidatechPharma PLC, IpsenPharma, Chiasma, Inc., Peptron, Inc., Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc., Pfizer Inc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.